October 22, 2020
Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis.
Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, of Ohio State University. Dr. Rovin also serves on the Protocol Review & Design Sub-Committee of the Lupus Clinical Investigators Network (LuCIN), managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance. Results showed that those patients with lupus nephritis treated with voclosporin in combination with standard therapy of mycophenolate mofetil and low-dose steroids had better and faster response rates than those who received the standard therapy alone. The effects were also seen among patients who are Hispanic, one of the groups at high risk for lupus nephritis.
Aurinia Pharmaceuticals noted in a press release that the data presented at ASN Kidney Week 2020 was submitted as part of voclosporin’s new drug application (NDA) to the United States Food and Drug Administration (FDA). The FDA accepted the NDA, agreed to Priority Review, and is expected to act on the application on January 22, 2021.